Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neurons

Clinical Neuropharmacology

Volumn 19, Issue 4, 1996, Pages 360-365

  Ling, Zao Dung ^a   Pieri, Sara C ^a   Carvey, Paul M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dopamine; Levodopa; Neurotoxicity; Parkinson's disease; Tissue culture; Tyrosine hydroxylase

Indexed keywords

DOPA; LEVODOPA; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ARTICLE; AUTOOXIDATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EMBRYO; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STEREOISOMERISM; TEGMENTUM;

EID: 0029953109     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619040-00010     Document Type: Article

References (23)

1. Fornstedt B, Brun A, Rosengren E, Carlsson A. The apparent autooxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm 1989;1:279-95.
2. Shoulson I. Neuroprotective clinical strategies for Parkinson's disease. Ann Neural 1992:32 (suppl):S143-5.
3. Ogawa N, Edamatsu R, Mizukawa K, Asanuma M, Kohno M, Mori A. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. Adv Neurol 1993;60:242-50.
4. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-12.
5. Graham DG, Tiffany SM, Bell WR, Gutknecht WF. Autooxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978;14:644-53.
6. Spina MB, Cohen G. Exposure of striatal synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharmacol Exp Ther 1988;247:502-7. [Erratum in J Pharmacol Exp Ther 1989;248:478].
7. Spina MB, Cohen G. Exposure of striatal synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharmacol Exp Ther 1988;247:502-7. [Erratum in J Pharmacol Exp Ther 1989;248:478].
8. Steece-Collier K, Collier TJ, Sladek CD, Sladek JR. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp Neurol 1990;110:201-8.
9. Michel PP. Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990;26:428-35.
10. Mena MA, Pardo B, Casarejos MJ, Fahn S, deYebenes JG. Neurotoxicity of levodopa on cate-cholamine-rich neurons. Mov Disord 1992;7:23-31.
11. Kontur PJ, Marek K, Roth R, Redmond DE. Effects of L-dopa and dopamine receptor agonists on cultured rat mesencephalic dopamine neurons. Neurology 1993;43:A153.
12. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993;8:129-33.
13. Olanow CW. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 1992;32(suppl):S2-9.
14. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA 1989;86:1398-400.
15. Yoshida M, Ogawa M, Suzuki K, Nagatsu T. Parkinsonism produced by tetrahydrorsoquinoline (TIQ) or the analogues. Adv Neurol 1993;60:207-11.
16. Carvey PM, Ptak LR, Kao L, Klawans HL. Striatal homogenates from animals chronically treated with haloperidol stimulate dopamine and GABA uptake in cultures of rostral mesencephalic tegmentum. Clin Neuropharmacol 1989;12:425-34.
17. Yu SJ, Lo ES, Cochran EJ, et al. Cerebrospinal fluid from patients with Parkinson's disease alters the survival of dopamine neurons in mesencephalic culture. Exp Neurol 1994;- 126:15-24.
18. Loeffler DA, DeMaggio AJ, Juneau PL, Havaich MK, LeWitt PA. Effects of enhanced striatal dopamine turnover in vivo on glulathione oxidation, Clin Neuropharmacol 1994:17:370-9.
19. Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of L-DOPA does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-5.
20. Blunt SB, Jenner P, Marsden CD. The effect of L-dopa and carbidopa treatment on the survival of rat fetai dopamine grafts assessed by tyrosine hydnwsylase immunohistochemistry and [3H]mazindol autoradiography. Neuroscience 1991;43:95-110.
21. Sahakian BJ, Carlson KR, DeGirolami U, Bhawan J. Functional and structural consequences of long-term dietary L-dopa treatment in mice. Commun Psychopharmacol 1980;4:169-76.
22. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 1984;43:990-3.
23. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br Med J 1995;311:1602-7.